Harry Heijerman

Utrecht University — Netherlands

Medicine · Health Sciences

41h-index10.6kcitations212works2.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cystic Fibrosis Research Advances(171), Neonatal Respiratory Health Research(34), Tracheal and airway disorders(28), Inhalation and Respiratory Drug Delivery(27), Pneumonia and Respiratory Infections(23)

Publications210 total

Three years of Elexacaftor/tezacaftor/ivacaftor decreases the presence of pathogens in sputum cultures and throat swabs
2025
Evaluation of Elexacafor/Tezacaftor/Ivacaftor therapy after lung transplantation in Cystic Fibrosis: The Dutch National KOALA study
JHLT Open·2025· 3 citedOpen Access
Scedosporium infection as a late complication after start of elexacaftor/tezacaftor/ivacaftor: two case reports
Respiratory Medicine Case Reports·2025Open Access
P285 Towards a better understanding of colorectal adenomas and cancer in cystic fibrosis
Journal of Cystic Fibrosis·2024
P073 Real-world use of the highly effective modulator therapy elexacaftor/tezacaftor/ivacaftor: a retrospective single-center observational study
Journal of Cystic Fibrosis·2024
WS01.03 Effects of elexacaftor/tezacaftor/ivacaftor in lung transplant recipients with cystic fibrosis: the Dutch national KOALA study
Journal of Cystic Fibrosis·2024
Considerations for the use of inhaled antibiotics for <i>Pseudomonas aeruginosa</i> in people with cystic fibrosis receiving CFTR modulator therapy
BMJ Open Respiratory Research·2024· 12 citedOpen Access
The Multicenter KOALA Study: The Effects of Kaftrio After Lung Transplantation in Cystic Fibrosis
The Journal of Heart and Lung Transplantation·2024· 1 citedOpen Access
Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study
Journal of Cystic Fibrosis·2024· 5 cited
Development and validation of a novel personalized electronic patient-reported outcome measure to assess quality of life (Q-LIFE): a prospective observational study in people with Cystic Fibrosis
EClinicalMedicine·2023· 5 citedOpen Access
Treatment with inhaled antibiotics in bronchiectasis, side effects, and evaluation of the tolerance test; analysis from the BATTLE randomized controlled trial
The Clinical Respiratory Journal·2023· 9 citedOpen Access
EPS6.08 Cystic fibrosis elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using Tacrolimus, a drug-drug interaction study
Journal of Cystic Fibrosis·2023Open Access
WS10.02 Pharmacological effects of CFTR-modulation in cystic fibrosis patients after lung transplantation: interim results of the multicenter KOALA study
Journal of Cystic Fibrosis·2023Open Access
P049 Effects of elexacaftor/tezacaftor/ivacaftor after 6 months in Dutch people with cystic fibrosis with at least 1 F508del mutation
Journal of Cystic Fibrosis·2023Open Access
P152 Development and validation of a personalised electronic patient-reported outcome measure to assess individual quality of life
Journal of Cystic Fibrosis·2023Open Access
P109 Real-life efficacy of elexacaftor/tezacaftor/ivacaftor in the Dutch cystic fibrosis population
Journal of Cystic Fibrosis·2023Open Access
Radiological and long‐term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease
Pediatric Pulmonology·2023· 9 citedOpen Access
The effect of azithromycin on sputum inflammatory markers in bronchiectasis
BMC Pulmonary Medicine·2023· 10 citedOpen Access
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
The Lancet Respiratory Medicine·2023· 62 citedOpen Access
The effect of azithromycin on sputum inflammatory markers in bronchiectasis. Analysis from the BAT randomized controlled trial
Research Square (Research Square)·2023Open Access
page 1 of 11Next →

Frequent Co-authors

Daan J. Touw(9), Cornelis K. van der Ent(9), Christof J. Majoor(8), Henderik W. Frijlink(8), P.P.H. Le Brun(7), Eva Van Braeckel(6), Anne H. de Boer(6), Evelien Kruisselbrink(5), Jeffrey M. Beekman(5), Elsbeth M. Westerman(5), R.W. Brimicombe(5), Marleen Bakker(4), Petrus Merkus(4), Gerd Döring(4), Johanna F. Dekkers(4), Gitte Berkers(4), Annelotte M. Vonk(4), Hettie M. Janssens(4), Karin M. de Winter‐de Groot(4), Steven Conway(4)